Hence, as recommended from the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, sac/val is recommended as a replacement for an ACE-inhibitor in patients with HFrEF to reduce the risk of HF hospitalization and death [46]. The gene discussed is ACE; the disease is congestive heart failure.